South Africa’s NHLS restarts antivenom production to combat critical global shortage

SOUTH AFRICA—The National Health Laboratory Service (NHLS) of South Africa, through its subsidiary South African Vaccine Producers (SAVP), has successfully restarted antivenom production at its refurbished manufacturing facility.

This revival responds to the critical shortage of snake antivenom that has impacted both South Africa and many other regions globally over the past years.

Antivenom remains the only effective treatment for severe venomous snakebites, as confirmed by the African Snakebite Institute.

It works by enhancing the body’s immune response to neutralize the toxins injected by snakes.

 The lack of sufficient antivenom supply has posed a significant public health challenge, with snakebite envenomation causing substantial morbidity and mortality in affected populations.

Production resumed two weeks ago with the release of the first batch, totaling 536 units of polyvalent antivenom.

This polyvalent antivenom is designed to treat bites from several types of venomous snakes commonly encountered in the region.

 The NHLS assured that additional batches are currently in production, promising a steady improvement in supply in the upcoming months.

The organization outlined the various stages involved in the manufacturing process, emphasizing the complexity and the rigorous quality control measures applied to each vial.

These extensive inspections at multiple production phases ensure the safety, efficacy, and quality of the antivenom, which is vital given its role as a lifesaving treatment.

Beyond snake antivenom, the NHLS also plans to release antivenoms targeting scorpion and spider envenomation.

In addition, boomslang antivenom, specifically for bites from the boomslang snake, is expected.

All these products are anticipated to become available by November this year.

Globally, antivenom shortages have been exacerbated by factors such as limited production capacities, high manufacturing costs, and logistical challenges.

The South African initiative to restore local production aligns with efforts worldwide to improve access to antivenoms, particularly in regions where snakebites remain a neglected public health issue.

Recent reports indicate that the global antivenom market is valued at approximately USD 500 million, reflecting its crucial role in tropical and subtropical areas.

Continued investment in manufacturing facilities and supply chain improvements is essential to meet rising demand and reduce fatalities caused by venomous animal bites.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and beyond. Also, follow us on our WhatsApp channel for updates.